deucravacitinib,apremilast
bms,amgen
['psoriasis', 'deucrava', 'deucra', 'bristol']
bristol myers squibb - u.s. food and drug administration approves sotyktu (deucravacitinib), oral treatment for adults with moderate-to-severe plaque psoriasis 
IPC provides clinicians with resources and training to best manage their psoriasis patients and conducts research into the disease to improve care worldwide.